{
    "Clinical Trial ID": "NCT00494481",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Vandetanib Plus Docetaxel",
        "  vandetanib 100 mg plus docetaxel",
        "INTERVENTION 2: ",
        "  Placebo Plus Docetaxel",
        "  placebo plus docetaxel"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Females with histological/cytological confirmation of breast cancer.",
        "  Subjects with a measurable lesion or bone lesions",
        "Exclusion Criteria:",
        "  Previous radiotherapy within 6 weeks",
        "  Significant cardiac events, arrhythmias or other cardiac conditions"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Patients With a Disease Progression Event",
        "  Number of patients with objective disease progression or death (by any cause in the absence of objective progression)",
        "  Time frame: RECIST tumour assessments carried out at screening (within 3 weeks before the 1st dose) and then as per site clinical practice until objective progression. The only additional mandatory RECIST assessment is at the point of data cut-off",
        "Results 1: ",
        "  Arm/Group Title: Vandetanib Plus Docetaxel",
        "  Arm/Group Description: vandetanib 100 mg plus docetaxel",
        "  Overall Number of Participants Analyzed: 35",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  24",
        "Results 2: ",
        "  Arm/Group Title: Placebo Plus Docetaxel",
        "  Arm/Group Description: placebo plus docetaxel",
        "  Overall Number of Participants Analyzed: 29",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  18"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 14/33 (42.42%)",
        "  Neutropenia 4/33 (12.12%)",
        "  Febrile Neutropenia 3/33 (9.09%)",
        "  Granulocytopenia 0/33 (0.00%)",
        "  Atrial Fibrillation 1/33 (3.03%)",
        "  Vertigo 1/33 (3.03%)",
        "  Keratitis 1/33 (3.03%)",
        "  Diarrhoea 3/33 (9.09%)",
        "  Colitis 0/33 (0.00%)",
        "  Ileus 1/33 (3.03%)",
        "  Nausea 1/33 (3.03%)",
        "  Stomatitis 1/33 (3.03%)",
        "  Asthenia 1/33 (3.03%)",
        "  Fatigue 1/33 (3.03%)",
        "Adverse Events 2:",
        "  Total: 12/29 (41.38%)",
        "  Neutropenia 2/29 (6.90%)",
        "  Febrile Neutropenia 1/29 (3.45%)",
        "  Granulocytopenia 1/29 (3.45%)",
        "  Atrial Fibrillation 1/29 (3.45%)",
        "  Vertigo 0/29 (0.00%)",
        "  Keratitis 0/29 (0.00%)",
        "  Diarrhoea 0/29 (0.00%)",
        "  Colitis 1/29 (3.45%)",
        "  Ileus 0/29 (0.00%)",
        "  Nausea 0/29 (0.00%)",
        "  Stomatitis 0/29 (0.00%)",
        "  Asthenia 0/29 (0.00%)",
        "  Fatigue 0/29 (0.00%)",
        "  Pyrexia 1/29 (3.45%)"
    ]
}